ASGCT Annual Meeting Abstract Categories

When submitting an abstract, authors will select one topic from the list below that best describes their abstract:

A - Viral Vector Development

• A1 - Viral Vectors (excluding AAV – including lentivirus and other RNA viruses, adenovirus, herpesvirus, bocavirus, and chimetic vectors)
• A2 - AAV Vectors - Virology and Vectorology (Excluding CNS)
• A3 - AAV Vectors - Capsid Engineering
• A4 - AAV Vectors - Preclinical and Proof-of-Concept In-Vivo Studies (Excluding Non-Human Primates)
• A5 - AAV Vectors - Non-Human Primates and Large Animal Models
• A6 - AAV Vectors - Manufacturing New Technologies
• A7 - AAV Vectors - Immune Modulation 

B - Disease Models and Clinical Applications

• B1 - Metabolic Diseases (including Diabetes)
• B2 - Liver Genetic Diseases (including Hemophilia)
• B3 - Lysosomal Storage Diseases
• B4 - Heart, Lung, and Kidney Diseases
• B5 - Neurologic Diseases - Vectorology (excluding Ophthalmic and Auditory Diseases) 
• B6 - Neurological Disease Models (excluding Ophthalmic, auditory, and vectorology)
• B7 - Ophthalmic and Auditory Diseases
• B8 - Musculo-skeletal Diseases
• B9 - Genetic Disorders of the Blood and Immune System (Including hemoglobinopathies, hematopoietic lineages, and inherited immune deficiencies)  
• B10 - Organoids and IPS models of Disease 

C - Gene Targeting and Gene Correction

• C1 - Base Editing and Prime Editing
• C2 - Epigenetic Editing and RNA Editing 
• C3 - Genome Editing (including disruption, excision, and insertion – HDR)
• C4 - On- and Off-Target Method Development
• C5 - Gene Targeting and Gene Correction New Technologies 

D - Oligonucleotides

• D - Oligonucleotide Therapeutics (including siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, splice switching oligos, plasmids)  

E - Nonviral Delivery

• E1 - Lipid nanoparticles (including Engineering, therapeutic delivery, Manufacturing, CMC considerations)
• E2 - Physical delivery methods and DNA/RNA drug dvelopment (including electroporation, ultrasound, other enhanced physical methods of delivery, DNA/RNA modifications, and RNPs) 
• E3 - Exosomes, VLPs and Nanoagents (including extracellular vesicles, microvesicles, synthetic polymers, but excluding LNPs) 

F - Cancer

• F1 - Cancer - Immunotherapy and Cancer Vaccines
• F2 - Cancer - Oncolytic Viruses
• F3 - Cancer - Targeted Gene and Cell Therapy 
• F4 - Cancer – CAR/TCR in T/NK and other immune cell types for Solid Tumors 
• F5 - Cancer – CAR/TCR in T/NK and other immune cell types for Hematologic Malignancies 

G - Immunology

• G1 - Challenges to Immunological Responses to Therapeutic Interventions (Includes host responses, therapy/prevention of infectious diseases, nucleic acid therapy, RNA-based Therapies; excludes cancer immunotherapy and cancer vaccines) 
• G2 - CAR/TCR in T/NK and other immune cell types for Autoimmune and Infectious Diseases (Including immune targeting) 

H - Cell Therapy

• H1 - Cell Therapies with or without Ex-Vivo Genetic Manipulation
• H2 - In-Vivo Editing of HSPCs and Immune Cells

I – CMC & Clinical Translation

• I1 - Vector Product Engineering, Development and Manufacturing (excluding AAV) 
• I2 - Cell Therapy Product Engineering, Development and Manufacturing
• I3 - Pharmacology/Toxicology Studies and Analytics/Assay Development
• I4 - Molecular and Cellular Methods (Including assess vector integration, genome integrity, and outcomes) 
• I5 - Chemistry, Manufacturing, and Controls (INCLUDING Vector & Cell Therapy, Formulation, Supply Chain)  

J - Clinical Trials

• J1 - Gene Therapy Trials - In-Vivo Gene Therapy Modification
• J2 - Cell Therapy and Cell-Based Gene Therapy Trials